Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Pediatr Blood Cancer. 2012 Jul 1;58(7):1099-105. doi: 10.1002/pbc.24116. Epub 2012 Feb 29.
Neuroblastoma is the most common extracranial solid tumor of childhood, and the outcomes for children with high-risk and relapsed disease remain poor. However, new international strategies for risk stratification and for treatment based on novel tumor targets and including immunotherapy are being employed in attempts to improve the outcomes of children with neuroblastoma. A new international neuroblastoma risk classification system has been developed which is being incorporated into cooperative group clinical trials in North America, Japan, and Europe, resulting in standardized approaches for the initial evaluation and treatment stratification of neuroblastoma patients. Furthermore, novel treatment regimens are being developed based on improved understanding of neuroblastoma biology and on the recruitment of the immune system to specifically target neuroblastoma tumors. These approaches will lead to new therapeutic strategies that likely will improve the outcomes for children with neuroblastoma worldwide.
神经母细胞瘤是儿童最常见的颅外实体瘤，高危和复发患儿的预后仍然较差。然而，目前正在采用新的国际风险分层策略和基于新型肿瘤靶点的治疗策略，包括免疫疗法，试图改善神经母细胞瘤患儿的预后。已经开发出一种新的国际神经母细胞瘤风险分类系统，正在北美、日本和欧洲的合作组临床试验中实施，从而为神经母细胞瘤患者的初始评估和治疗分层提供了标准化方法。此外，正在根据对神经母细胞瘤生物学的深入了解和招募免疫系统来专门针对神经母细胞瘤肿瘤制定新的治疗方案。这些方法将带来新的治疗策略，可能会改善全球神经母细胞瘤患儿的预后。
